Ham-milton
Bluelighter
- Joined
- Jul 20, 2007
- Messages
- 5,746
Generic products for Oxycontin® were approved in March, 2004, by the FDA. Teva was granted 180 days of generic exclusivity for its generic 80 mg oxycodone extended-release tablet. The product was launched shortly after its approval. Endo was granted this exclusivity for the other oxycodone extended-release tablet strengths but did not launch its products until June, 2005, after a final court ruling. In February, 2006, the court of appeals re-evaluated their previous ruling, and sent the case back for further review. As a result, patents covering Oxycontin® could be deemed enforceable. A settlement agreement with IMPAX, another manufacturer of generic Oxycontin®, has not been announced. Watson has an authorized generic product that will likely be removed from the market along the same timeline with the other generic products. On August 29, 2006, Endo and Teva announced patent settlement agreements with Purdue Pharma for their generic Oxycontin® tablets. Both manufacturers, as part of these agreements, will discontinue sale of these products. By December 31, 2006, Endo will stop selling its product and Teva announced discontinuation at a future date. In exchange for discontinuing sale of their generic products, both of these manufacturers will be released from all liability for infringement of Purdue’s patents.
from: https://www.fhsc.com/news/ClinicalAlerts/CA_2006-09.pdf